

# Allegation: Instruction To Find Answers “Before Tomorrow”

## Massachusetts AG FAC 1229:

229. Meanwhile, staff gave Jonathan, Kathe, Mortimer and Richard Sackler projections indicating that OxyContin sales could plateau. Mortimer demanded answers to a series of questions about why sales would not grow. **Richard chimed in at 8:30 p.m. to instruct the staff to find answers “before tomorrow.”** Staff emailed among themselves about how the Sacklers’ demands were unrealistic and harmful and then decided it was safer to discuss the problem by phone.

our formulation. Why are we playing catch up ...? Shouldn't we have studies like this ...?<sup>133</sup>  
The Sacklers decided not to do the research because they wanted the profits from a new product.

ed. Richard didn't want a paper trail, so he instructed  
Stewart met with his staff to plan how to phrase a carefully  
Stewart wrote to Richard that reformulating OxyContin “will  
taking too many pills.”<sup>135</sup>  
Jonathan, Kathe, Mortimer and Richard Sackler projections  
plateau.<sup>136</sup> Mortimer demanded answers to a series of  
now.<sup>137</sup> **Richard chimed in at 8:30 p.m. to instruct the staff**  
Staff emailed among themselves about how the Sacklers’  
and then decided it was safer to discuss the problem by

PPLPC013000244843-844.  
PPLPC013000244843 (“My sentiments exactly the first time I read it.  
yourself what it means. I think you may come to a very different  
out it. Give me a call at home.”); 2008-02-13 email from John

P012000172201. Five years later, Purdue published two studies  
included the crush-proof tablets lowered the risks of addiction.  
One. One was a single-session research study conducted by three  
consultant to assess “the attractiveness” of the crush-proof tablets to  
and users were interviewed by two researchers. “This study did not  
situations, and no drugs were administered.” Participants’ answers to  
crush-proof tablets “might be less attractive to recreational opioid  
concluded that “among the available opioid products that we included  
crush-proof OxyContin tablets) to be the least attractive, the least  
likelihood for tampering and the lowest street value.”  
the same Purdue authors, 29 volunteers snorted OxyContin (original  
per a seven-day treatment phase and rated the drugs. The study

concluded that “reformulated OxyContin has a reduced abuse potential compared to the original formulation upon  
intranasal administration.” PPN00002051, -2044. Purdue amended its OxyContin label to reference these studies  
in 2013.

<sup>134</sup> 2008-02-26 email from Edward Mahoney, PPLPC012000172585; attachment PPLPC012000172587.

<sup>135</sup> 2008-02-26 email from Mortimer Sackler, PPLPC12000172674.

<sup>136</sup> 2008-02-26 email from Richard Sackler, PPLPC12000172674.

<sup>137</sup> 2008-02-26 email from John Stewart, PPLPC012000172677.

# Irrelevant 2008 Email Requests Information About Sales, Not Marketing

**From:** Sackler, Dr Richard  
**Sent:** Tuesday, February 26, 2008 8:32 PM  
**To:** Sackler, Mortimer JR; Mahony, Edward; Stewart, John H. (US); sdb; Strassburger, Philip; Dolan, James; Gasdia, Russell; Sackler, Jonathan; Sackler, Dr Kathe  
**Cc:** Fogel, David; Bostrup, Eric; Lowne, Jon; mcm; Shum, Sam  
**Subject:** RE: **Bank Presentation** 02272008 v6.ppt

Ed, if you can repair this before tomorrow, it would be very welcome.

- **OIG confirmed compliance for 2008**

**From:** Mahony, Edward  
**Sent:** Tuesday, February 26, 2008 9:59 PM  
**To:** Sackler, Dr Richard; Sackler, Mortimer JR; Stewart, John H. (US); sdb; Strassburger, Philip; Dolan, James; Gasdia, Russell; Sackler, Jonathan; Sackler, Dr Kathe  
**Cc:** Fogel, David; Bostrup, Eric; Lowne, Jon; mcm; Shum, Sam  
**Subject:** RE: Bank Presentation 02272008 v6.ppt

Dr Richard please see my response.

Best Regards,

**From:** Sackler, Dr Richard  
**Sent:** Tuesday, February 26, 2008 8:32 PM  
**To:** Sackler, Mortimer JR; Mahony, Edward; Stewart, John H. (US); sdb; Strassburger, Philip; Dolan, James; Gasdia, Russell; Sackler, Jonathan; Sackler, Dr Kathe  
**Cc:** Fogel, David; Bostrup, Eric; Lowne, Jon; mcm; Shum, Sam  
**Subject:** RE: Bank Presentation 02272008 v6.ppt

CONFIDENTIAL

PPLPC012000172673

2/26/08 Email from R. Sackler (PPLPC012000172674)